Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 5CNS 3Plasma cell 2Other solid neoplasm 2Breast 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Lymphedema 1Head and Neck Neoplasms 1Fibrosis 1

Interventions

pembrolizumab 183Cisplatin 159Radiotherapy 77Carboplatin 71Radiotherapy, Intensity-Modulated 70Cetuximab 68Magnetic Resonance Spectroscopy 65Nivolumab 64Paclitaxel 52Docetaxel 50Specimen Handling 45Radiation 34Gemcitabine 33Fluorouracil 31Surveys and Questionnaires 28Biopsy 27toripalimab 26Drug Therapy 26Platinum 25Surgical Procedures, Operative 24Standard of Care 231,2-diaminocyclohexaneplatinum II citrate 23cemiplimab 22atezolizumab 20Capecitabine 20Ipilimumab 19Chemoradiotherapy 19tislelizumab 18durvalumab 18Taxes 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pharmaceutical Preparations × Head & Neck × 1 year × Clear all
NCT06912763 2026-01-26

Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)

M.D. Anderson Cancer Center

Phase 2 Recruiting
250 enrolled
Head & Neck

Fibrosis, Head and Neck Neoplasms, Lymphedema

Data powered by HemOnc (CC BY 4.0) Colophon âš¡